Summary

The Drugs for Malaria Market is valued at US$ 1.11 billion in 2025 and is projected to grow at a CAGR of 4.9% to reach US$ 1.74 billion by 2034.

Overview:
The Drugs for Malaria market encompasses fast-acting schizonticidal agents for acute treatment, radical-cure agents targeting hypnozoites, chemoprevention in vulnerable groups, and severe-malaria interventions. Frontline therapy remains artemisinin-based combination therapies (ACTs) in fixed-dose, adult and pediatric dispersible forms, with rectal artesunate as a pre-referral option and IV artesunate as the severe-malaria standard. For Plasmodium vivax, radical cure relies on 8-aminoquinolines paired with G6PD testing to mitigate hemolysis risk, while seasonal malaria chemoprevention and intermittent preventive treatment support public-health objectives. Key trends include vigilance against artemisinin partial resistance and partner-drug reduced susceptibility, evaluation of triple-ACTs, development of next-generation combinations with novel mechanisms, and broader adoption of point-of-care G6PD diagnostics enabling single-encounter radical cure models. Market access is shaped by large donor-funded tenders, stringent quality assurance and prequalification, heat-stable packaging for Zone IVb climates, and growing interest in local or regional manufacturing for supply resilience. Competitive dynamics blend innovator pipelines, global generics with WHO-prequalified facilities, and specialized pediatric formulation expertise. Differentiation centers on clinical efficacy in resistant settings, safety across age/physiologic groups, dose simplicity, pharmacokinetic robustness, and price discipline under pooled procurement. Digital tools - electronic LMIS, e-vouchers, and adherence messaging - improve forecasting and correct use. Over the medium term, performance hinges on resistance management, procurement reliability, diagnostic-linked radical cure, and the readiness of health systems to deploy newer regimens within stewardship frameworks.

Key Insights:
• ACTs remain the therapeutic backbone
Fixed-dose ACTs deliver rapid parasite clearance and operational simplicity. Supplier credibility rests on bioequivalence data, heat-stability, and consistent delivery into donor and public-sector channels.

• Managing resistance pressure
Signals of artemisinin partial resistance and partner-drug erosion drive rotation policies, pharmacovigilance, and evaluation of triple-ACTs. Programs prioritize efficacy surveillance and buffer stocks for swift policy updates.

• Severe malaria standard of care
IV artesunate dominates for hospital management, with rectal artesunate bridging pre-referral gaps. Reliability of steriles supply, nurse training, and dosing accuracy determine outcomes.

• Radical cure for P. vivax
Introducing 8-aminoquinolines alongside scalable G6PD testing enables hypnozoite clearance and relapse prevention. One-visit models improve completion and reduce recurrent episodes.

• Chemoprevention as policy tool
Seasonal chemoprevention and intermittent preventive treatment cut incidence in high-risk geographies. Success depends on timely campaign logistics, caregiver education, and pharmacovigilance.

• Pediatric and adherence design
Dispersible tablets, weight-band dosing, and taste-masking enhance acceptance. Blister calendars and SMS prompts support completion of multi-day regimens.

• Supply security and QA
WHO prequalification, independent QC, and serialization underpin trust. Multi-sourcing APIs, semi-synthetic artemisinin options, and regional fill-finish mitigate shocks.

• Procurement economics
Pooled tenders compress prices yet reward proven on-time, in-full performance. Framework agreements, volume flex clauses, and equitable allocation stabilize pipelines.

• Pipeline diversification
Novel actives, next-gen partners, and triple combinations seek durability in resistant settings. Target product profiles emphasize single-course cures, pediatric suitability, and safety latitude.

• Diagnostics–therapy nexus
Widespread RDT use guides ACT deployment; G6PD testing unlocks safe radical cure. Data systems linking test results to dispensing improve stewardship and forecasting.

Regional Analysis:
North America
Market activity centers on treatment for travelers and migrants, hospital protocols for severe malaria, and limited public-health use. Access relies on specialty distribution, emergency stock management, and clinician education on dosing and drug–drug interactions. Research funding, policy guidance, and donor commitments influence global supply security. Pharmacovigilance networks and stewardship messaging shape appropriate duration and follow-up.

Europe
Similar to North America, demand is predominantly for imported or travel-related cases, with strong emphasis on guideline adherence and hospital readiness for severe malaria. Procurement favors quality-assured ACTs, IV artesunate, and access to radical-cure options with G6PD testing. Public funding and global health partnerships support manufacturing resilience and surveillance. Training and migrant-health services ensure timely diagnosis and treatment.

Asia-Pacific
A heterogeneous landscape: Greater Mekong Subregion focuses on resistance containment and targeted drug policy, while South Asia and Pacific islands balance falciparum and vivax management. Scale-up of G6PD testing expands radical-cure coverage. Public tenders and local manufacturing capacity shape availability, with pediatric dispersibles and community case management central to uptake. Data systems and cross-border coordination remain critical.

Middle East & Africa
Largest public-health demand with high falciparum burden. National programs depend on donor-funded ACT procurement, severe-malaria readiness with IV artesunate, and seasonal chemoprevention where epidemiology supports it. Supply chains prioritize heat-stable packs, last-mile delivery, and stock visibility. Ongoing resistance monitoring and timely guideline updates underpin efficacy and case-management quality.

South & Central America
P. vivax predominance elevates radical-cure strategies with integrated G6PD testing. Amazon and border regions require robust community case management and reliable access to ACTs for mixed infections. Procurement blends public tenders and regional manufacturing to manage lead times. Surveillance, vector control coordination, and adherence support reduce relapse and transmission risk.

ページTOPに戻る

Table of Contents

1. Table of Contents
1.1 List of Tables
1.2 List of Figures

2. Global Drugs for Malaria Market Summary, 2025
2.1 Drugs for Malaria Industry Overview
2.1.1 Global Drugs for Malaria Market Revenues (In US$ billion)
2.2 Drugs for Malaria Market Scope
2.3 Research Methodology

3. Drugs for Malaria Market Insights, 2024-2034
3.1 Drugs for Malaria Market Drivers
3.2 Drugs for Malaria Market Restraints
3.3 Drugs for Malaria Market Opportunities
3.4 Drugs for Malaria Market Challenges
3.5 Tariff Impact on Global Drugs for Malaria Supply Chain Patterns

4. Drugs for Malaria Market Analytics
4.1 Drugs for Malaria Market Size and Share, Key Products, 2025 Vs 2034
4.2 Drugs for Malaria Market Size and Share, Dominant Applications, 2025 Vs 2034
4.3 Drugs for Malaria Market Size and Share, Leading End Uses, 2025 Vs 2034
4.4 Drugs for Malaria Market Size and Share, High Growth Countries, 2025 Vs 2034
4.5 Five Forces Analysis for Global Drugs for Malaria Market
4.5.1 Drugs for Malaria Industry Attractiveness Index, 2025
4.5.2 Drugs for Malaria Supplier Intelligence
4.5.3 Drugs for Malaria Buyer Intelligence
4.5.4 Drugs for Malaria Competition Intelligence
4.5.5 Drugs for Malaria Product Alternatives and Substitutes Intelligence
4.5.6 Drugs for Malaria Market Entry Intelligence

5. Global Drugs for Malaria Market Statistics – Industry Revenue, Market Share, Growth Trends and Forecast by segments, to 2034
5.1 World Drugs for Malaria Market Size, Potential and Growth Outlook, 2024- 2034 ($ billion)
5.1 Global Drugs for Malaria Sales Outlook and CAGR Growth by Drug Class, 2024- 2034 ($ billion)
5.2 Global Drugs for Malaria Sales Outlook and CAGR Growth By Segmentation2, 2024- 2034 ($ billion)
5.3 Global Drugs for Malaria Sales Outlook and CAGR Growth By Segmentation3, 2024- 2034 ($ billion)
5.4 Global Drugs for Malaria Market Sales Outlook and Growth by Region, 2024- 2034 ($ billion)

6. Asia Pacific Drugs for Malaria Industry Statistics – Market Size, Share, Competition and Outlook
6.1 Asia Pacific Drugs for Malaria Market Insights, 2025
6.2 Asia Pacific Drugs for Malaria Market Revenue Forecast by Drug Class, 2024- 2034 (USD billion)
6.3 Asia Pacific Drugs for Malaria Market Revenue Forecast By Segmentation2, 2024- 2034 (USD billion)
6.4 Asia Pacific Drugs for Malaria Market Revenue Forecast By Segmentation3, 2024- 2034 (USD billion)
6.5 Asia Pacific Drugs for Malaria Market Revenue Forecast by Country, 2024- 2034 (USD billion)
6.5.1 China Drugs for Malaria Market Size, Opportunities, Growth 2024- 2034
6.5.2 India Drugs for Malaria Market Size, Opportunities, Growth 2024- 2034
6.5.3 Japan Drugs for Malaria Market Size, Opportunities, Growth 2024- 2034
6.5.4 Australia Drugs for Malaria Market Size, Opportunities, Growth 2024- 2034

7. Europe Drugs for Malaria Market Data, Penetration, and Business Prospects to 2034
7.1 Europe Drugs for Malaria Market Key Findings, 2025
7.2 Europe Drugs for Malaria Market Size and Percentage Breakdown by Drug Class, 2024- 2034 (USD billion)
7.3 Europe Drugs for Malaria Market Size and Percentage Breakdown By Segmentation2, 2024- 2034 (USD billion)
7.4 Europe Drugs for Malaria Market Size and Percentage Breakdown By Segmentation3, 2024- 2034 (USD billion)
7.5 Europe Drugs for Malaria Market Size and Percentage Breakdown by Country, 2024- 2034 (USD billion)
7.5.1 Germany Drugs for Malaria Market Size, Trends, Growth Outlook to 2034
7.5.2 United Kingdom Drugs for Malaria Market Size, Trends, Growth Outlook to 2034
7.5.2 France Drugs for Malaria Market Size, Trends, Growth Outlook to 2034
7.5.2 Italy Drugs for Malaria Market Size, Trends, Growth Outlook to 2034
7.5.2 Spain Drugs for Malaria Market Size, Trends, Growth Outlook to 2034

8. North America Drugs for Malaria Market Size, Growth Trends, and Future Prospects to 2034
8.1 North America Snapshot, 2025
8.2 North America Drugs for Malaria Market Analysis and Outlook by Drug Class, 2024- 2034 ($ billion)
8.3 North America Drugs for Malaria Market Analysis and Outlook By Segmentation2, 2024- 2034 ($ billion)
8.4 North America Drugs for Malaria Market Analysis and Outlook By Segmentation3, 2024- 2034 ($ billion)
8.5 North America Drugs for Malaria Market Analysis and Outlook by Country, 2024- 2034 ($ billion)
8.5.1 United States Drugs for Malaria Market Size, Share, Growth Trends and Forecast, 2024- 2034
8.5.1 Canada Drugs for Malaria Market Size, Share, Growth Trends and Forecast, 2024- 2034
8.5.1 Mexico Drugs for Malaria Market Size, Share, Growth Trends and Forecast, 2024- 2034

9. South and Central America Drugs for Malaria Market Drivers, Challenges, and Future Prospects
9.1 Latin America Drugs for Malaria Market Data, 2025
9.2 Latin America Drugs for Malaria Market Future by Drug Class, 2024- 2034 ($ billion)
9.3 Latin America Drugs for Malaria Market Future By Segmentation2, 2024- 2034 ($ billion)
9.4 Latin America Drugs for Malaria Market Future By Segmentation3, 2024- 2034 ($ billion)
9.5 Latin America Drugs for Malaria Market Future by Country, 2024- 2034 ($ billion)
9.5.1 Brazil Drugs for Malaria Market Size, Share and Opportunities to 2034
9.5.2 Argentina Drugs for Malaria Market Size, Share and Opportunities to 2034

10. Middle East Africa Drugs for Malaria Market Outlook and Growth Prospects
10.1 Middle East Africa Overview, 2025
10.2 Middle East Africa Drugs for Malaria Market Statistics by Drug Class, 2024- 2034 (USD billion)
10.3 Middle East Africa Drugs for Malaria Market Statistics By Segmentation2, 2024- 2034 (USD billion)
10.4 Middle East Africa Drugs for Malaria Market Statistics By Segmentation3, 2024- 2034 (USD billion)
10.5 Middle East Africa Drugs for Malaria Market Statistics by Country, 2024- 2034 (USD billion)
10.5.1 Middle East Drugs for Malaria Market Value, Trends, Growth Forecasts to 2034
10.5.2 Africa Drugs for Malaria Market Value, Trends, Growth Forecasts to 2034

11. Drugs for Malaria Market Structure and Competitive Landscape
11.1 Key Companies in Drugs for Malaria Industry
11.2 Drugs for Malaria Business Overview
11.3 Drugs for Malaria Product Portfolio Analysis
11.4 Financial Analysis
11.5 SWOT Analysis

12 Appendix
12.1 Global Drugs for Malaria Market Volume (Tons)
12.1 Global Drugs for Malaria Trade and Price Analysis
12.2 Drugs for Malaria Parent Market and Other Relevant Analysis
12.3 Publisher Expertise
12.2 Drugs for Malaria Industry Report Sources and Methodology